- Home
- RLTY vs PRQR Comparison
RLTY vs PRQR Comparison
Compare RLTY & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- PRQR
- Stock Information
- Founded
- RLTY 2022
- PRQR 2012
- Country
- RLTY United States
- PRQR Netherlands
- Employees
- RLTY N/A
- PRQR N/A
- Industry
- RLTY Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- PRQR Health Care
- Exchange
- RLTY Nasdaq
- PRQR Nasdaq
- Market Cap
- RLTY 255.0M
- PRQR 232.8M
- IPO Year
- RLTY N/A
- PRQR 2014
- Fundamental
- Price
- RLTY $15.47
- PRQR $2.06
- Analyst Decision
- RLTY
- PRQR Strong Buy
- Analyst Count
- RLTY 0
- PRQR 8
- Target Price
- RLTY N/A
- PRQR $8.88
- AVG Volume (30 Days)
- RLTY 86.7K
- PRQR 368.1K
- Earning Date
- RLTY 01-01-0001
- PRQR 11-06-2025
- Dividend Yield
- RLTY 9.35%
- PRQR N/A
- EPS Growth
- RLTY N/A
- PRQR N/A
- EPS
- RLTY N/A
- PRQR N/A
- Revenue
- RLTY N/A
- PRQR $20,129,184.00
- Revenue This Year
- RLTY N/A
- PRQR N/A
- Revenue Next Year
- RLTY N/A
- PRQR N/A
- P/E Ratio
- RLTY N/A
- PRQR N/A
- Revenue Growth
- RLTY N/A
- PRQR 8.65
- 52 Week Low
- RLTY $11.38
- PRQR $1.07
- 52 Week High
- RLTY $14.60
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- RLTY 47.93
- PRQR 42.63
- Support Level
- RLTY $15.42
- PRQR $1.91
- Resistance Level
- RLTY $15.83
- PRQR $2.50
- Average True Range (ATR)
- RLTY 0.17
- PRQR 0.16
- MACD
- RLTY -0.01
- PRQR -0.04
- Stochastic Oscillator
- RLTY 13.35
- PRQR 25.42
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.